BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.68% | -5.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.68% | -5.97% | |||
| Cost of Revenue | -204.27% | 76.48% | |||
| Gross Profit | 538.91% | -55.92% | |||
| SG&A Expenses | 20.77% | 15.56% | |||
| Depreciation & Amortization | -0.02% | 0.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.61% | 50.01% | |||
| Operating Income | 521.15% | -116.86% | |||
| Income Before Tax | -3.15% | -108.84% | |||
| Income Tax Expenses | 339.37% | -92.29% | |||
| Earnings from Continuing Operations | -51.49% | -112.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -51.49% | -112.78% | |||
| EBIT | 521.15% | -116.86% | |||
| EBITDA | 843.42% | -109.55% | |||
| EPS Basic | -51.34% | -112.77% | |||
| Normalized Basic EPS | 912.25% | -108.83% | |||
| EPS Diluted | -51.34% | -113.02% | |||
| Normalized Diluted EPS | 912.25% | -109.07% | |||
| Average Basic Shares Outstanding | 0.10% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.10% | -2.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||